Progress in systemic therapy for breast cancer: An overview and perspectives

European Journal of Cancer, Supplement

Volumn 1, Issue 2, 2003, Pages 56-69

  Piccart, M J ^a   Cardoso, F ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Review

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; ANTIMETABOLITE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CANERTINIB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EXEMESTANE; FLUOROPYRIMIDINE; FLUOROURACIL; FULVESTRANT; GEFITINIB; LETROZOLE; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN; NAVELBINE; OSI 779; PACLITAXEL; PK 1116; SEMAXANIB; SORAFENIB; TAK 165; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VOROZOLE;

ADVANCED CANCER; ANOREXIA; APPETITE DISORDER; BIOLOGICAL THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EARLY CANCER; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HOT FLUSH; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; SWEATING; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

EID: 2442528624     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00009-0     Document Type: Article

References (130)

1. Giuliano A.E., Kirgan D.M., Guenther J.M., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann. Surg. 220:1994;391-398
2. Krag D., Weaver D., Alex J., et al. Surgical resection and radiolocalisation of sentinel lymph node in breast cancer using a gama probe. Soc. Surg. Oncol. 47:1994;32
3. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 276:1996;1818-1822
4. Kapteijn B.A.E., Nieweg O.E., Peterse J.L., et al. Sequential lymphatic dissemination of breast cancer. Eur. J. Sur. Oncol. 22:1996;399
5. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 349:1997;1864-1867
6. Nieweg O.E., Jansen L., Valdes Olmos R.A., et al. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur. J. Nucl. Med. 26(Suppl. 4):1999;S11-S16
7. Veronesi U., Orecchia R., Luini A., et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur. J. Cancer. 37:2001;2178-2183
8. Gatzemeier W., Orecchia R., Gatti G., Intra M., Veronesi U. Intraoperative radiotherapy (IORT) in treatment of breast carcinoma - a new therapeutic alternative within the scope of breast-saving therapy? Current status and future prospects. Report of experiences from the European Institute of Oncology (EIO), Mailand. Strahlenther Onkol. 177:2001;330-337
9. Reitsamer R., Peintinger F., Sedlmayer F., et al. Intraoperative radiotherapy (IORT) after breast conserving therapy in breast cancer patients. Eur. J. Cancer. 37:2001;S209. (abstr 767)
10. Bartelink H. Intensity modulated radiation therapy (IMRT) in breast cancer. Eur. J. Cancer. 37:2001;S134. (abstr 491)
11. Vrieling C., Collette L., Fourquet A., et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother. Oncol. 55:2000;219-232
12. Howell A., Osborne C.K., Morris C., et al. ICI 182, 780 (Faslodex®). Development of a novel, "pure" antiestrogen Cancer. 89:2000;817-828
13. Howell A., DeFriend D., Robertson J., et al. Response to a specific antiestrogen (ICI 182, 780) in tamoxifen-resistant breast cancer. Lancet. 345:1995;29-30
14. Howell A., Robertson J.F.R., Albano J.Q., et al. Comparison of efficacy and tolerability of fulvestrant (Faslodex®) with anastrozole (Arimidex®) in postmenopausal women (PM) with advanced breast cancer (ABC) - preliminary results. Breast Cancer Res. Treat. 64:2000;27. (abstr 6)
15. Osborne CK, on behalf of the North American Faslodex® Investigator Group. A double-blind randomised trial comparing the efficacy and tolerability of Faslodex® (Fulvestrant) with Arimidex® (Anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 64(1): 27, 2000 (abstr 7).
16. Osborne K., Zhao H., Fuqua S. Selective estrogen receptor modulators. structure, function, and clinical use J. Clin. Oncol. 18:2000;3172-3186
17. Robertson J.F.R., Howell A., Owers R., et al. Survival update from a phase II trial of fulvestrant (Faslodex®) in tamoxifen-resistant breast cancer patients. Breast Cancer Res. Treat. 69:2001;289. (abstr 451)
18. Mauriac L. Fulvestrant (Faslodex®) is effective in postmenopausal patients with visceral metastases. comparison with anastrozole Breast Cancer Res. Treat. 69:2001;289. (abstr 452)
19. Jones S, on behalf of the 0020 and 0021 investigators. Fulvestrant (Faslodex®) versus anastrozole (Arimidex®) for the treatment of advanced breast cancer in postmenopausal women - safety update on the combined analysis of two multicenter trials. Breast Cancer Res Treat 69, 290, 2001 (abstr 455).
20. Buzdar A.U., Jones S.E., Vogel C.L., et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer. 15:1997;730-739
21. Dombernowsky P., Smith I., Falkson, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16:1998;453-461
22. Goss P.E., Winer E.P., Tannock I.F., et al. Randomised phase III trial comparing the new potent and selective third-generation aromatase inhibitor Vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. J. Clin. Oncol. 17:1999;52-63
23. Kaufmann M., Bajetta E., Dirix L.Y., et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer. results of a phase III randomised double-blind trial J. Clin. Oncol. 18:2000;1399-1411
24. Buzdar A., Douma J., Davidson N., et al. Phase III, multicenter, double-blind, randomised study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19:2001;3357-3366
25. Bergh J., Bonneterre J., Illiger H.J., et al. Vorozole (RIVIZOR) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc. Am. Soc. Clin. Oncol. 16:1997;155a. (abstr 543)
26. Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor. randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer Ann. Oncol. 9:1998;639-645
27. Hamilton A., Piccart M. The third generation non-steroidal aromatase inhibitors. a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer Ann Oncol. 10:1999;377-384
28. Nabholtz J.M., Buzdar A.U., Pollak M., et al. Anastrozole is superior to tamoxifen as first line treatment for advanced breast cancer in postmenopausal women. results of North American Multicenter Randomised Trial J. Clin. Oncol. 18:2000;3758-3767
29. Bonneterre J., Thurliman B., Robertson J.F.R., et al. Anastrozole versus tamoxifen as first line treatment for advanced breast cancer in 668 postmenopausal women. results of the tamoxifen or Arimidex randomised Group Efficacy and Tolerability Study J. Clin. Oncol. 18:2000;3748-3757
30. Milla-Santos A., Milla L., Rallo L., et al. Anastrozole vs tamoxifen in hormonodependent advanced breast cancer. A phase II randomised trial. Breast Cancer Res. Treat. 64:2000;54. (abstr 173)
31. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. results of a phase III study of the International Letrozole Breast Cancer Group J. Clin. Oncol. 19:2001;2596-2606
32. Mouridsen H., Sun Y., Gershanovich M., et al. Final analysis of the double-blind, randomised, multinational phase III trials of letrozole (Femara®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res. Treat. 69:2001;211. (abstr 9)
33. Paridaens R., Dirix L., Beex L., et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer. a randomised phase II EORTC trial with a tamoxifen control Clin. Breast Cancer. 1(Suppl. 1):2000;S19-S21
34. Howell A., Robertson J.F.R., Quaresma Albano J., et al. Comparison of efficacy and tolerability of Faslodex™ (ICI 182, 780) with Arimidex™ (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC) - preliminary results. Breast Cancer Res. Treat. 34:2000;27. (abstr 6)
35. Osborne CK, Pippen J, Jones SE, et al. Faslodex (ICI 182, 780) shows longer duration of response compared with Arimidex (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC) - preliminary results of a phase III N. American trial. Breast Cancer Res Treat (in press).
36. Fan S., Cherney B., Reinhold W., et al. Disruption of p53 function in immortalised human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin. Cancer Res. 4:1998;1047-1054
37. Lanni J.S., Lowe S.W., Licitra E.J., et al. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 94:1997;9679-9683
38. Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1:1995;506-526
39. O'Connor P.M., Jackman J., Bae I., et al. Characterisation of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Anticancer Research. 57:1997;4285-4300
40. Nabholtz J.M., Senn H.J., Bezwoda W.R., et al. Prospective randomised trial of docetaxel versus mitomycin plus vinblastine in patients with MBC progressing despite previous anthracycline-containing chemotherapy. J. Clin. Oncol. 17:1999;1413-1424
41. Sjostrom J., Blomqvist C., Mouridsen H., et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure. a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur. J. Cancer. 35:1999;1194-1201
42. Monnier A., Bonneterre J., Roche H., et al. Phase III study. taxotere (TXT) versus 5-fluorouracil+navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results) Ann. Oncol. 9(Suppl. 4):1998;12
43. Leonard R., Cervantes G., Lui W., et al. Survival update of so14999 a large phase III trial of capecitabine/docetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC) Eur. J. Cancer. 37(Suppl. 6):2001;S151. (abstr 551)
44. Bishop J., Dewar J., Toner G., et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J. Clin. Oncol. 17:1999;2355-2364
45. Paridaens R., Biganzoli L., Bruning P., et al. Paclitaxel versus Doxorubicin as first line single-agent chemotherapy for metastatic breast cancer. a European Organisation for Research and Treatment of Cancer randomised study with cross-over J. Clin. Oncol. 18:2000;724-733
46. Sledge G.W., Neuberg D., Ingle J., et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer (MBC). an intergroup trial (E1193) J. Clin. Oncol. 21:2003;588-592
47. Chan S., Friedrichs K., Noel D., et al. Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 17:1999;2341-2354
48. Nabholtz J.M., Flakson G., Campos D., et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC. Proc. Am. Soc. Clin. Oncol. 18:1999;127a. (abstr 485)
49. Luck H.J., Thomssen C., Untch M., et al. Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the AGO Breast Cancer Group. Proc. Am. Soc. Clin. Oncol. 19:2000;73a. (abstr 280)
50. Dieras V., Tubiana-Hulin M., Bougnoux P., et al. 6 Cycles of epirubicin/taxotere (ET) versus 6 cycles of 5FU/epirubicin/cyclophosphamide (FEC) as first line metastatic breast cancer (MBC) treatment. Preliminary results of a randomised phase II trial Breast Cancer Res. Treat. 64:2000;79. (abstr 314)
51. Biganzoli L., Cuffer T., Bruning R., et al. Doxorubicin (A)/taxol (T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC). a phase III trial Proc. Am. Soc. Clin. Oncol. 19:2000;73a. (abstr 282)
52. Carmichael J. UKCCCR Trial of epirubicin and cyclophosphamide (EC) Vs epirubicin and Taxol (ET) in first line treatment of women with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20:2001;22a. (abstr 84)
53. Nabholtz J.A., Paterson A., Dirix L., et al. A phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to FAC as first line chemotherapy (CT for patients (Pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20:2001;22a. (abstr 83)
54. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first line therapy for women with metastatic breast cancer. final results of a randomised phase III multicenter trial J. Clin. Oncol. 19:2001;1707-1715
55. Cardoso F, Di Leo A, Lohrisch C, et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Annals of Oncology 2002, 13, 197-207.
56. Spielmann M., Martin M., Namer M., et al. Activity of MTA (multitargeted antifolate, LY231514) in metastatic breast cancer (MBC) patients previously treated with an anthracycline and a taxane. Breast Cancer Res. Treat. 57:1999;123. (abstr 517)
57. Theodoulou M., Llombart A., Cruciani G., et al. Pemetrexed disodium (ALIMTA, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients (pts) with prior anthracycline or anthracenedione and taxane treatment. phase II study Proc. Am. Soc. Clin. Oncol. 19:2000;130a. (abstr 506)
58. Miles D.W., Smith I.E., Coleman R.E., et al. P phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur. J. Cancer. 37:2001;1366-1371
59. Chou T.C., Zhang X.G., Harris C.R., et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory topaclitaxel. Proc. Natl. Acad. Sci. USA. 95:1998;15798-15802
60. Bollag D.M., McQueney P.A., Zhu J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333
61. Kowalski R.J., Giannakakou P., Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J. Biol. Chem. 272:1997;2534-2541
62. Lee F.Y., Borzilleri R., Fairchild C.R., et al. BMS-247550. a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin. Cancer Res. 7:2001;1429-1437
63. Awada A., Burris H., de Valeriola D., et al. Phase I clinical and pharmacology study of the novel epothylone BMS-247550 given weekly in patients with advanced solid tumors. Proc. AACR-NCI-EORTC International Conference. 2001;. (abstr 779)
64. Jacobs T.W., Gown A.M., Yaziji H., et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am. J. Clin. Pathol. 113:2000;251-258
65. Gancberg D, Järvinen T, Di Leo A, et al. Evaluation of her-2/neu protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of her-2/neu testing. Breast Cancer Res Treat 2002, 1(4), 257-268.
66. Leyland-Jones B., Arnold A., Gelmon K., Verma S., Rakhit A., Howell J. A pharmacokinetic (PK) study of Herceptin® administered with paclitaxel i.v. every 3 week. Eur. J. Cancer. 36(Suppl. 5):2000;S53. (abstr 41)
67. Leyland-Jones B., Hemmings F., Arnold A., Veram S., Ayoub J.P. Pharmacokinetics of Herceptin Administered with Paclitaxel every three weeks. Breast Cancer Res. Treat. 64:2000;124. (abstr 534)
68. Johnston S.R.D., Hickish T., Ellis P.A., et al. Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer - relationship with tumour phenotype. Breast Cancer Res. Treat. 64:2000;32. (abstr 28)
69. Piccart-Gebhart M.J., Branle F., Valeriola D., et al. A phase I, clinical and pharmacokinetic (PK), trial of the farnesyl transferase inhibitor (FTI) R115777+docetaxel: a promising combination in patients (pts) with solid tumors Proc. Am. Soc. Clin. Oncol. 20:2001;80a. (abstr 318)
70. Schwartz G., Rowinsky E.K., Rha S.Y., et al. A phase I, pharmacokinetic, and biological correlative study of R115777 and trastuzumab (Herceptin) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;81a. (abstr 322)
71. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. 18:2000;1378-1391
72. Tripathy D. Bisphosphonates in oncology. breast cancer and beyond Semin. Oncol. 28(4 Suppl. 11):2001;86-91
73. Body J.J. Bisphosphonates. Eur. J. Cancer. 34:1998;263-269
74. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer. a systematic review of published randomised trials involving 31, 510 women J. Clin. Oncol. 16:1998;3439-3460
75. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N. Eng. J. Med. 344:2001;783-792
76. Nicholson R.I., Gee J.M.W., Barrow D., et al. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Clin. Cancer Res. 5(Suppl.):1999;. (abstr 740)
77. Adams J., Palombella V.T., Elliot P.J. Proteasome inhibition. a new strategy in cancer treatment Invest. New Drugs. 18:2000;109-121
78. Elliot P.J., Ross J.S. The proteasome. A novel target for novel drug therapies. Am. J. Clin. Pathol. 116:2001;637-646
79. Wright J., Hillsamer V.L., Gore-Langton R.E., et al. Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341. Oncology (Huntingt). 14:2000;1589-1597
80. Mimnaugh E.G., Chavany C., Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271:1996;22796-22801
81. Magnifico A., Tagliabue E., Ardini E., et al. Heregulin beta1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2 oncoprotein. FEBS Lett. 422:1998;129-131
82. Lenferink A.E., Simpson J.F., Shawver L.K., et al. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. USA. 97:2000;9609-9614
83. Biswas D.K., Dai S.C., Cruz A., et al. The nuclear factor kappa B (NF-kB). a potential therapeutic target for estrogen receptor negative breast cancers PNAS. 98:2001;10386-10391
84. Demetri G.D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type. results from a prospective community oncology study. Procrit Study Group J. Clin. Oncol. 16:1998;3412-3425
85. Molls M., Stadler P., Becker A., et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlentherapie Onkologie. 174(Suppl. IV):1998;13-16
86. Littlewood T.J., Bajetta E., Cella D. Efficacy and quality of life outcomes of epoietin-alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy. Proc. Am. Soc. Clin. Oncol. 18:1999;574a. (abstr 2217)
87. Raab G.H., Auer F., Scheich D., et al. Prospective analysis of the oxygenation of malignant breast tumors as a predictor of response to primary systemic chemotherapy (PSC). Breast Cancer Res. Treat. 64:2000;79. (abstr 313)
88. Littlewood T.J., Rapoport B., Bajetta E., et al. Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy. Proc. Am. Soc. Clin. Oncol. 19:2000;605a. (abstr 2381)
89. Ozer H., Armitage J.O., Bennet C.L., et al. Update of recommendations for the use of hematopoietic colony-stimulating factors. evidence-based, clinical practice guidelines J. Clin. Oncol. 18:2000;3558-3585
90. Green M., Joelbl H., Bselga J., et al. A randomised, double-blind, phase 3 study evaluating fixed-dose, once-per-cycle Pegylated filgrastim (SD/01) vs daily filgrastim to support chemotherapy for breast cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;23a. (abstr 90)
91. Holmes F.A., O'Shaughnessy J.A., Vukelja S., et al. Blinded, randomised, multicenter study to evaluate single administration pegfilgrastim once per cycle vs daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J. Clin. Oncol. 20:2002;727-731
92. National Institutes of Health Consensus Development Conference Statement Adjuvant therapy for breast cancer, 1-3 November, 2000. National Institutes of Health Consensus Development Panel. J. Nat. Cancer Inst. 93:2001;979-989
93. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights. international consensus panel on the treatment of primary cancer J. Clin. Oncol. 19:2001;3817-3827
94. Van't Veer L.J., Van de Vijver M.J., Dai H., et al. Expression profiling predicts poor outcome of disease in young breast cancer patients. Eur. J. Cancer. 37(Suppl. 6):2001;S271. (abstr 1000)
95. EBCTCG Polychemotherapy for early breast cancer. an overview of the randomised trials Lancet. 352:1998;930-942
96. Peto R. Fifth main meeting of the Early Breast Cancer Trialist's Collaborative Group. Oxford, UK, September 2000.
97. Cardoso F, Atalay G, Piccart MJ. Optimizing anthracycline therapy for node-positive breast cancer. Am J Cancer (in press).
98. Henderson I.C., Berry D., Demetri G., et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;101a. (abstr 390)
99. Henderson CI. Adjuvant chemotherapy: taxanes - the "Pro" position. In Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, 1-3 November 2000.
100. Tan A.R., Swain S.M. Adjuvant chemotherapy for breast cancer. an update Semin Oncol. 28:2001;359-376
101. Thomas E., Buzdar A., Theriault R., et al. Role of paclitaxel in adjuvant therapy of operable breast cancer. preliminary results of prospective randomised clinical trial Proc. Am. Soc. Clin. Oncol. 20:2000;74a. (abstr 285)
102. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary node. In Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer, 1-3 November 2000.
103. NSABP, Pittsburgh, PA. The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B 27. Oral session of the 24th Annual San Antonio Breast Cancer Symposium, December 2001.
104. Piccart M.J., Lohrisch C., Duchateau L., et al. Taxanes in the adjuvant treatment of breast cancer. why not yet J. Natl. Cancer Inst. Monographs. 30:2001;88-95
105. Baum M, on behalf of the ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women. Breast Cancer Res. Treat. 69, 210, 2001 (abstr 8).
106. Goldhirsch A., Glick J.H., Gelber R.D., Senn H.J. Meeting highlights. international consensus panel on treatment of primary breast cancer J. Natl. Cancer Inst. 90:1998;1601-1608
107. Scottish Cancer Trials Breast Group and ICRF breast unit, London Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II beast carcinoma. the Scottish trial The Lancet. 341:1993;1293-1298
108. Jakesz R., Hausmaninger H., Samonigg H., et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs CMF in premenopausal stage I and II hormone-responsive breast cancer patients. four-year results of Austrian Breast Cancer Study Group trial 5 Proc. Am. Soc. Clin. Oncol. 18:1999;67a. (abstr 250)
109. Ejlertsen B., Dombernowsky P., Mouridsen H.T., et al. Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proc. Am. Soc. Clin. Oncol. 18:1999;66a. (abstr 248)
110. Boccardo F., Rubagotti A., Amoroso D., et al. Cyclophosphamide, methotrexate and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients. results of the Italian Breast Cancer Adjuvant Study Group 02 randomised trial J. Clin. Oncol. 18:2000;2718-2727
111. Roche H.H., Kerbrat P., Bonneterre J., et al. Complete hormonal blockade versus chemotherapy in premenopausal early-stage cancer patients with positive hormone-receptor and 1-3 node-positive tumor. results of the FASG 06 trial Proc. Am. Soc. Clin. Oncol. 19:2000;72a. (abstr 279)
112. Jonat W. Node-positive breast cancer. preliminary efficacy, QoL and BMD results from the ZEBRA study. The ZEBRA (Zoladex Early Breast Cancer Research Association) Trialists' Group Breast Cancer Res. Treat. 64:2000;S29. (abstr 13)
113. Sverrisdóttir A., Fornander T., Rutqvist L.E. Bone mineral density in premenopausal patients in a randomised trial of adjuvant endocrine therapy (ZIPP-trial). Proc. Am. Soc. Clin. Oncol. 20:2001;25a. (abstr 96)
114. Heintz N.H., Leslie K.O., Rogers L.A., et al. Amplification of the c-erb B2 oncogene in prognosis of breast adenocarcinoma. Arch. Pathol. Lab. Med. 114:1990;160-163
115. Carlomagno C., Perrone F., Gallo C., et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol. 14:1996;2702-2708
116. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer. evidence from a phase III randomised trial J. Clin. Oncol. 19:2001;3808-3816
117. Gasparini G., Barbareschi M., Doglioni C., et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. 1:1995;189-198
118. Cardoso F., Di Leo A., Larsimont D., et al. Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer. Breast Cancer Res. Treat. 69:2001;243. (abstr 228)
119. Piccart M.J., Di Leo A., Hamilton A. HER2. a "predictive factor" ready to use in the daily management of breast cancer patients? Eur. J. Cancer. 36:2000;1755-1761
120. Di Leo A, Cardaso F, Scohy S, Piccart, MJ, et al. Predictive molecular markers: a new window of opportunity in the adjuvant therapy of breast cancer. In Naboltz JM, Tonkin K. Aapro MS, Buzdar AU. Breast Cancer Management - Application of Clinical and Translational Evidence to Patient Care. UK, AU Lippincott Williams and Williams, 2nd edn, 2003, pp. 367-380.
121. Jarvinen T.A.H., Kononen J., Pelto-Huikko M., et al. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erb B2 overexpression in breast cancer. Am. J. Pathol. 148:1996;2073-2082
122. Jarvinen T.A.H., Tanner M., Barlund M., et al. Characterisation of topoisomerase IIα gene amplification and deletion in breast cancer. Genes Chromosomes Cancer. 26:1999;142-150
123. Jarvinen T.A.H., Tanner M., Rantanen V., et al. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156:2000;839-847
124. Isola J.J., Tanner M., Holli K., et al. Amplification of topoisomerase IIα is a strong predictor of response to epirubicin-based chemotherapy in HER-2/neu positive breast cancer. Breast Cancer Res. Treat. 64:2000;31
125. Bernard C., Fellous A., Di Leo A., et al. Evaluation of microtubule associated parameters (MTAPs) as predictive markers for advanced breast cancer (ABC) patients treated with docetaxel. Eur. J. Cancer. 37(Suppl. 6):2001;S182. (abstr 666)
126. Kandioler D., Taucher S., Steiner B., et al. p-53 genotype and major response to anthracycline or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc. Am. Soc. Clin. Oncol. 17:1998;102a. (abstr 392)
127. Thor A.D., Berry D.A., Budman D.R., et al. erb-B2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90:1998;1346-1360
128. Clahsen P.C., Van de Velde C.J.H., Duval C., et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol. 16:1998;470-479
129. Lenz H.J., Leichman C.G., Danenberg K.D., et al. Thymidylate synthase m RNA level in adenocarcinoma of the stomach. a predictor for primary tumor response and overall survival J. Clin. Oncol. 14:1995;176-182
130. Fox S.B., Engels K., Comley M., et al. Relationship of elevated tumor thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann. Oncol. 8:1997;271-275